Atea Pharmaceuticals Inc

NAS:AVIR (USA)   Ordinary Shares
$ 3.96 +0.13 (+3.39%) 11:09 PM EST
At Loss
P/B:
0.60
Market Cap:
$ 333.52M
Enterprise V:
$ -253.13M
Volume:
164.50K
Avg Vol (2M):
301.38K
Volume:
164.50K
At Loss
Avg Vol (2M):
301.38K

Business Description

Atea Pharmaceuticals Inc
NAICS : 541714 SIC : 2833
ISIN : US04683R1068

Share Class Description:

AVIR: Ordinary Shares
Description
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).
Name Current Vs Industry Vs History
Cash-To-Debt 240.68
Equity-to-Asset 0.93
Debt-to-EBITDA -0.02
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year EBITDA Growth Rate -56.7
3-Year EPS without NRI Growth Rate -47.3
Name Current Vs Industry Vs History
5-Day RSI 83.78
9-Day RSI 70.11
14-Day RSI 60.11
6-1 Month Momentum % 19.27
12-1 Month Momentum % 20.37

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 18.24
Quick Ratio 18.24
Cash Ratio 17.86

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -0.4
Shareholder Yield % 0.16

Financials (Next Earnings Date:2024-05-08 Est.)

AVIR's 30-Y Financials
Income Statement Breakdown FY
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:AVIR

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Atea Pharmaceuticals Inc Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $)
EPS (TTM) ($) -1.64
Beta 0.5
Volatility % 49.6
14-Day RSI 60.11
14-Day ATR ($) 0.125207
20-Day SMA ($) 3.7565
12-1 Month Momentum % 20.37
52-Week Range ($) 2.765 - 5.19
Shares Outstanding (Mil) 84.22

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Atea Pharmaceuticals Inc Filings

Filing Date Document Date Form
No Filing Data

Atea Pharmaceuticals Inc Stock Events

Financials Calendars
Event Date Price($)
No Event Data

Atea Pharmaceuticals Inc Frequently Asked Questions

What is Atea Pharmaceuticals Inc(AVIR)'s stock price today?
The current price of AVIR is $3.96. The 52 week high of AVIR is $5.19 and 52 week low is $2.77.
When is next earnings date of Atea Pharmaceuticals Inc(AVIR)?
The next earnings date of Atea Pharmaceuticals Inc(AVIR) is 2024-05-08 Est..
Does Atea Pharmaceuticals Inc(AVIR) pay dividends? If so, how much?
Atea Pharmaceuticals Inc(AVIR) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1